|
US6660753B2
(en)
|
1999-08-19 |
2003-12-09 |
Nps Pharmaceuticals, Inc. |
Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
PL369598A1
(en)
*
|
2001-02-21 |
2005-05-02 |
Nps Pharmaceuticals, Inc. |
Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
US6916821B2
(en)
|
2001-04-02 |
2005-07-12 |
Brown University |
Methods of treating disorders with Group I mGluR antagonists
|
|
CA2442478C
(en)
|
2001-04-02 |
2010-02-02 |
Mark F. Bear |
Use of group i mglur antagonists in the treatment of fragile x syndrome, autism, mental retardation
|
|
EP1458708B1
(en)
*
|
2001-12-18 |
2007-09-26 |
Merck & Co., Inc. |
Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
|
|
JP4286146B2
(ja)
*
|
2001-12-18 |
2009-06-24 |
メルク エンド カムパニー インコーポレーテッド |
メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤
|
|
EP1458385A4
(en)
*
|
2001-12-19 |
2005-12-21 |
Merck & Co Inc |
METABOTROPIC GLUTAMATE RECEPTOR 5-HETEROARYL-SUBSTITUTED IMIDAZOLE MODULATORS
|
|
EP1485093B1
(en)
*
|
2002-03-12 |
2010-11-03 |
Merck Sharp & Dohme Corp. |
Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
|
|
US7964609B2
(en)
|
2002-06-20 |
2011-06-21 |
Astrazeneca Ab |
Use of mGluR5 antagonists for the treatment of gerd
|
|
SE0201943D0
(sv)
*
|
2002-06-20 |
2002-06-20 |
Astrazeneca Ab |
New use
|
|
CN1691944A
(zh)
*
|
2002-08-09 |
2005-11-02 |
阿斯利康(瑞典)有限公司 |
作为代谢型谷氨酸受体－5调节剂的噁二唑
|
|
WO2004014881A2
(en)
|
2002-08-09 |
2004-02-19 |
Astra Zeneca Ab |
'1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
|
|
AU2003264018A1
(en)
|
2002-08-09 |
2004-02-25 |
Astrazeneca Ab |
Compounds having an activity at metabotropic glutamate receptors
|
|
GB0303503D0
(en)
*
|
2003-02-14 |
2003-03-19 |
Novartis Ag |
Organic compounds
|
|
CN100537564C
(zh)
*
|
2003-04-04 |
2009-09-09 |
麦克公司 |
代谢型谷氨酸受体-5的二芳基取代三唑调节剂
|
|
CA2524867A1
(en)
*
|
2003-05-15 |
2004-12-02 |
Merck & Co., Inc. |
3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
|
|
WO2005060961A2
(en)
*
|
2003-12-18 |
2005-07-07 |
Astrazeneca Ab |
Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
|
|
US8207147B2
(en)
|
2003-12-24 |
2012-06-26 |
Prosidion Limited |
Heterocyclic derivatives as GPCR receptor agonists
|
|
SG149900A1
(en)
*
|
2004-02-18 |
2009-02-27 |
Astrazeneca Ab |
Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
ATE402935T1
(de)
*
|
2004-02-18 |
2008-08-15 |
Astrazeneca Ab |
Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen
|
|
US7585881B2
(en)
|
2004-02-18 |
2009-09-08 |
Astrazeneca Ab |
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
TW200538108A
(en)
|
2004-02-19 |
2005-12-01 |
Astrazeneca Ab |
Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
WO2006004142A1
(ja)
*
|
2004-06-30 |
2006-01-12 |
Banyu Pharmaceutical Co., Ltd. |
ビアリール誘導体
|
|
KR100621192B1
(ko)
*
|
2004-10-13 |
2006-09-19 |
한국화학연구원 |
무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법
|
|
JP4557685B2
(ja)
|
2004-11-15 |
2010-10-06 |
独立行政法人理化学研究所 |
蛍光蛋白質
|
|
ES2346685T3
(es)
|
2005-01-14 |
2010-10-19 |
F. Hoffmann-La Roche Ag |
Deribados de tiazol-4-carboxamida como antagonistas de mglur5.
|
|
GB0510142D0
(en)
*
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds A1
|
|
WO2007001973A1
(en)
*
|
2005-06-28 |
2007-01-04 |
Astrazeneca Ab |
New use
|
|
WO2007013830A1
(en)
|
2005-07-26 |
2007-02-01 |
Portela & Ca. S.A. |
Nitrocatechol derivatives as comt inhibitors
|
|
UY29796A1
(es)
|
2005-09-29 |
2007-04-30 |
Astrazeneca Ab |
Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
|
|
CN101291939B
(zh)
|
2005-11-08 |
2013-02-13 |
弗·哈夫曼-拉罗切有限公司 |
作为mGluR5受体拮抗剂的噻唑并[4,5-C]吡啶衍生物
|
|
US7951824B2
(en)
|
2006-02-17 |
2011-05-31 |
Hoffman-La Roche Inc. |
4-aryl-pyridine-2-carboxyamide derivatives
|
|
EP2003132B1
(en)
*
|
2006-04-03 |
2014-03-05 |
Astellas Pharma Inc. |
Oxadiazole derivatives as S1P1 agonists
|
|
EP1845097A1
(en)
|
2006-04-10 |
2007-10-17 |
Portela & Ca., S.A. |
Oxadiazole derivatives as COMT inhibitors
|
|
WO2008028903A2
(en)
*
|
2006-09-04 |
2008-03-13 |
Neurosearch A/S |
Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
|
|
JP5253401B2
(ja)
|
2006-09-07 |
2013-07-31 |
アクテリオン ファーマシューティカルズ リミテッド |
免疫調節薬としてのピリジン−４−イル誘導体
|
|
CL2007002594A1
(es)
|
2006-09-08 |
2008-06-06 |
Actelion Pharmaceuticals Ltd |
Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
|
|
CA2662673A1
(en)
|
2006-09-21 |
2008-03-27 |
Martin Bolli |
Phenyl derivatives and their use as immunomodulators
|
|
DK2481410T3
(en)
|
2007-01-31 |
2016-10-24 |
Bial - Portela & Ca S A |
Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
|
|
DK2125797T3
(da)
|
2007-03-16 |
2014-02-10 |
Actelion Pharmaceuticals Ltd |
Aminopyridinderivater som s1p1/edg1-receptoragonister
|
|
EP2195311B1
(en)
*
|
2007-08-17 |
2011-03-23 |
Actelion Pharmaceuticals Ltd. |
Pyridine derivatives as s1p1/edg1 receptor modulators
|
|
WO2009058298A1
(en)
|
2007-10-31 |
2009-05-07 |
Merck & Co., Inc. |
P2x3, receptor antagonists for treatment of pain
|
|
BRPI0818804A2
(pt)
|
2007-11-01 |
2015-04-22 |
Actelion Pharmaceuticals Ltd |
Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
|
|
HRP20120457T1
(hr)
*
|
2007-12-20 |
2012-06-30 |
Bayer Pharma Aktiengesellschaft |
4-(4-cijano-2-tioaril)dihidropirimidinoni i njihova uporaba
|
|
EP2254572B1
(en)
*
|
2008-02-07 |
2013-10-16 |
Massachusetts Eye & Ear Infirmary |
Compounds that enhance atoh-1 expression
|
|
MX2010009645A
(es)
|
2008-03-07 |
2010-09-28 |
Actelion Pharmaceuticals Ltd |
Derivados novedosos de aminometil benceno.
|
|
BRPI0908731A2
(pt)
|
2008-03-17 |
2017-05-16 |
Bial - Portela & C A S A |
formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol
|
|
CA2741666C
(en)
|
2008-10-31 |
2017-04-11 |
Merck Sharp & Dohme Corp. |
P2x3, receptor antagonists for treatment of pain
|
|
DE102009041241A1
(de)
|
2009-09-11 |
2011-08-04 |
Bayer Schering Pharma Aktiengesellschaft, 13353 |
Substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102008057344A1
(de)
|
2008-11-14 |
2010-05-20 |
Bayer Schering Pharma Aktiengesellschaft |
Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102009041242A1
(de)
|
2009-09-11 |
2011-12-15 |
Bayer Schering Pharma Aktiengesellschaft |
Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102008057343A1
(de)
|
2008-11-14 |
2010-05-20 |
Bayer Schering Pharma Aktiengesellschaft |
Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102008057364A1
(de)
|
2008-11-14 |
2010-05-20 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte Aryl-Verbindungen und ihre Verwendung
|
|
JP2012521429A
(ja)
|
2009-03-23 |
2012-09-13 |
メルク・シャープ・エンド・ドーム・コーポレイション |
疼痛治療用のｐ２ｘ３受容体アンタゴニスト
|
|
US8946231B2
(en)
|
2009-03-23 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
P2X3, receptor antagonists for treatment of pain
|
|
WO2010111058A1
(en)
|
2009-03-23 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
P2x3, receptor antagonists for treatment of pain
|
|
CN102448444B
(zh)
|
2009-04-01 |
2016-05-25 |
巴尔-波特拉及康邦亚股份有限公司 |
包括硝基儿茶酚衍生物的药物制剂及其制备方法
|
|
CA2758587A1
(en)
*
|
2009-04-13 |
2010-10-21 |
Irm Llc |
Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
|
|
TWI410421B
(zh)
|
2009-07-16 |
2013-10-01 |
Actelion Pharmaceuticals Ltd |
吡啶－４－基衍生物
|
|
US20130058915A1
(en)
|
2010-03-02 |
2013-03-07 |
Children's Medica Center Corporation |
Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
|
|
CA2818470C
(en)
|
2011-01-19 |
2019-03-05 |
Actelion Pharmaceuticals Ltd |
2-methoxy-pyridin-4-yl derivatives
|
|
US20140045900A1
(en)
|
2011-02-11 |
2014-02-13 |
Bial-Portela & Ca, S.A. |
Administration regime for nitrocatechols
|
|
US9126988B2
(en)
|
2011-12-13 |
2015-09-08 |
Bial—Portela & Ca, S.A. |
Intermediate for preparing a catechol-O-methyltransferase inhibitor
|
|
JP5946288B2
(ja)
*
|
2012-02-24 |
2016-07-06 |
公立大学法人名古屋市立大学 |
新規ヒドロキサム酸誘導体及びその用途
|
|
CN105143214B
(zh)
*
|
2013-02-15 |
2018-04-03 |
孟山都技术公司 |
用于控制线虫害虫的3,5‑二取代的‑4,5‑二氢‑1,2,4‑噁二唑
|
|
EP2853532B1
(en)
*
|
2013-09-28 |
2020-12-09 |
Instytut Farmakologii Polskiej Akademii Nauk |
1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
|
|
WO2016083863A1
(en)
|
2014-11-28 |
2016-06-02 |
Bial - Portela & Ca, S.A. |
Medicaments for slowing parkinson's disease
|
|
ES2770348T3
(es)
|
2015-05-20 |
2020-07-01 |
Idorsia Pharmaceuticals Ltd |
Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol
|
|
MY195177A
(en)
|
2015-06-23 |
2023-01-11 |
Kissei Pharmaceutical |
Pyrazole Derivative or Pharmaceutically Acceptable Salt Thereof
|
|
ES2975136T3
(es)
*
|
2016-03-30 |
2024-07-03 |
Sinntaxis AB |
Moduladores alost alostéricos negativos de MGLUR5 para uso en el tratamiento de daños cerebrales maduros
|
|
WO2019197468A1
(en)
*
|
2018-04-12 |
2019-10-17 |
Bayer Aktiengesellschaft |
N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides
|
|
KR102276327B1
(ko)
*
|
2019-06-25 |
2021-07-12 |
연세대학교 산학협력단 |
신규 옥사다이아졸 화합물 및 이를 포함하는 당뇨 예방 또는 치료용 조성물
|
|
BR112022003959A2
(pt)
*
|
2019-09-05 |
2022-05-24 |
Trevena Inc |
Métodos para tratamento de epilepsia
|